Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
As insulin prices continue to soar, many insurance companies are raising deductibles and changing which prescription brands they cover, according to USA Today.
Researchers from Baltimore-based Johns Hopkins University have determined that large bags of blood products can maintain temperature and cellular integrity during transportation by drones.
Today your focus is on more than materials management and purchasing. Documentation in the OR, Unique Device Identification, patient safety, and the latest medical breakthroughs are now sitting on your plate – demanding attention but with no indicators of what…
Carla Endicott, Vice President of Services and Operations of Cardinal Health Inventory Management Solutions at Cardinal Health
An antibiotic manufactured by Chapel Hill, N.C.-based Cempra has been rejected by the Food and Drug Administration, according to Reuters.
The U.S. Food and Drug Administration on Dec. 27 issued a warning to healthcare professionals and administrators of the potential safety risks associated with battery-powered mobile medical carts following reports of explosions, fires, smoking or overheating of equipment.
The opioid overdose antidote naloxone — also known by its brand name Narcan — is now available without prescription at Missouri's two largest pharmacy chains, according to KSDK.
New York City-based Pfizer and Russia-based NovaMedica completed a long-term strategic partnership to transfer the rights and technologies for the production of more than 30 drugs from Pfizer's to NovaMedica's portfolio.
Former Turing Pharmaceuticals CEO Martin Shkreli gained notoriety in the healthcare industry for raising the price of Daraprim, a generic anti-parasite drug for treating toxoplasmosis, from $13.50 per pill to $750 overnight. Despite immense public pushback, Mr. Shkreli says he…
The U.S. Food and Drug Administration granted first-time approval to a drug designed to treat patients suffering from spinal muscular atrophy on Dec. 23.
The Food and Drug Administration is imposing a clinical hold on several of Seattle Genetics' early-stage studies involving an experimental cancer drug following the deaths of four people, Reuters reported.